Logo image of AMRX

AMNEAL PHARMACEUTICALS INC (AMRX) Stock Fundamental Analysis

USA - NASDAQ:AMRX - US03168L1052 - Common Stock

9.81 USD
0 (0%)
Last: 9/19/2025, 8:00:00 PM
9.75 USD
-0.06 (-0.61%)
After Hours: 9/19/2025, 8:00:00 PM
Fundamental Rating

5

Taking everything into account, AMRX scores 5 out of 10 in our fundamental rating. AMRX was compared to 197 industry peers in the Pharmaceuticals industry. AMRX has a medium profitability rating, but doesn't score so well on its financial health evaluation. AMRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

AMRX had positive earnings in the past year.
AMRX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: AMRX reported negative net income in multiple years.
AMRX had a positive operating cash flow in each of the past 5 years.
AMRX Yearly Net Income VS EBIT VS OCF VS FCFAMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

AMRX has a Return On Assets of 0.10%. This is in the better half of the industry: AMRX outperforms 79.70% of its industry peers.
Looking at the Return On Invested Capital, with a value of 11.52%, AMRX belongs to the top of the industry, outperforming 88.32% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for AMRX is significantly below the industry average of 15.28%.
The last Return On Invested Capital (11.52%) for AMRX is above the 3 year average (7.98%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.1%
ROE N/A
ROIC 11.52%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
AMRX Yearly ROA, ROE, ROICAMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300 -400

1.3 Margins

AMRX's Profit Margin of 0.12% is fine compared to the rest of the industry. AMRX outperforms 79.70% of its industry peers.
AMRX has a Operating Margin of 13.31%. This is amongst the best in the industry. AMRX outperforms 84.77% of its industry peers.
In the last couple of years the Operating Margin of AMRX has grown nicely.
AMRX has a Gross Margin of 37.67%. This is comparable to the rest of the industry: AMRX outperforms 59.39% of its industry peers.
In the last couple of years the Gross Margin of AMRX has grown nicely.
Industry RankSector Rank
OM 13.31%
PM (TTM) 0.12%
GM 37.67%
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
AMRX Yearly Profit, Operating, Gross MarginsAMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMRX is creating some value.
Compared to 1 year ago, AMRX has less shares outstanding
AMRX has more shares outstanding than it did 5 years ago.
AMRX has a better debt/assets ratio than last year.
AMRX Yearly Shares OutstandingAMRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AMRX Yearly Total Debt VS Total AssetsAMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of 1.66, we must say that AMRX is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.66, AMRX is doing good in the industry, outperforming 62.44% of the companies in the same industry.
The Debt to FCF ratio of AMRX is 9.66, which is on the high side as it means it would take AMRX, 9.66 years of fcf income to pay off all of its debts.
AMRX's Debt to FCF ratio of 9.66 is fine compared to the rest of the industry. AMRX outperforms 79.70% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 9.66
Altman-Z 1.66
ROIC/WACC1.04
WACC11.09%
AMRX Yearly LT Debt VS Equity VS FCFAMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

A Current Ratio of 1.43 indicates that AMRX should not have too much problems paying its short term obligations.
AMRX's Current ratio of 1.43 is on the low side compared to the rest of the industry. AMRX is outperformed by 68.53% of its industry peers.
AMRX has a Quick Ratio of 1.43. This is a bad value and indicates that AMRX is not financially healthy enough and could expect problems in meeting its short term obligations.
AMRX has a Quick ratio of 0.88. This is in the lower half of the industry: AMRX underperforms 77.16% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 0.88
AMRX Yearly Current Assets VS Current LiabilitesAMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

AMRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.46%, which is quite good.
The Earnings Per Share has been growing by 10.63% on average over the past years. This is quite good.
Looking at the last year, AMRX shows a quite strong growth in Revenue. The Revenue has grown by 16.73% in the last year.
AMRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.43% yearly.
EPS 1Y (TTM)17.46%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%56.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%3.24%

3.2 Future

AMRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.95% yearly.
Based on estimates for the next years, AMRX will show a small growth in Revenue. The Revenue will grow by 0.60% on average per year.
EPS Next Y31.02%
EPS Next 2Y25.98%
EPS Next 3Y24.22%
EPS Next 5Y11.95%
Revenue Next Year8.32%
Revenue Next 2Y7.29%
Revenue Next 3Y7.7%
Revenue Next 5Y0.6%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMRX Yearly Revenue VS EstimatesAMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
AMRX Yearly EPS VS EstimatesAMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 13.26, AMRX is valued correctly.
Based on the Price/Earnings ratio, AMRX is valued cheaper than 88.32% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.38, AMRX is valued rather cheaply.
A Price/Forward Earnings ratio of 10.66 indicates a reasonable valuation of AMRX.
Based on the Price/Forward Earnings ratio, AMRX is valued cheaply inside the industry as 85.28% of the companies are valued more expensively.
AMRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 13.26
Fwd PE 10.66
AMRX Price Earnings VS Forward Price EarningsAMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

90.36% of the companies in the same industry are more expensive than AMRX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, AMRX is valued cheaper than 88.83% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.78
EV/EBITDA 8.39
AMRX Per share dataAMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

AMRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of AMRX may justify a higher PE ratio.
A more expensive valuation may be justified as AMRX's earnings are expected to grow with 24.22% in the coming years.
PEG (NY)0.43
PEG (5Y)1.25
EPS Next 2Y25.98%
EPS Next 3Y24.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (9/19/2025, 8:00:00 PM)

After market: 9.75 -0.06 (-0.61%)

9.81

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-07 2025-11-07/bmo
Inst Owners39.86%
Inst Owner Change4.6%
Ins Owners46.58%
Ins Owner Change-3.84%
Market Cap3.08B
Analysts82
Price Target12.24 (24.77%)
Short Float %3.28%
Short Ratio3.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.21%
Min EPS beat(2)40.06%
Max EPS beat(2)40.37%
EPS beat(4)3
Avg EPS beat(4)18.44%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)29.41%
EPS beat(12)10
Avg EPS beat(12)26.58%
EPS beat(16)11
Avg EPS beat(16)18.46%
Revenue beat(2)0
Avg Revenue beat(2)-4.66%
Min Revenue beat(2)-4.71%
Max Revenue beat(2)-4.6%
Revenue beat(4)1
Avg Revenue beat(4)-2.31%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)4
Avg Revenue beat(8)-0.35%
Revenue beat(12)7
Avg Revenue beat(12)0.09%
Revenue beat(16)8
Avg Revenue beat(16)-0.43%
PT rev (1m)2.13%
PT rev (3m)2.86%
EPS NQ rev (1m)-1.56%
EPS NQ rev (3m)-9.13%
EPS NY rev (1m)0%
EPS NY rev (3m)5.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.26%
Valuation
Industry RankSector Rank
PE 13.26
Fwd PE 10.66
P/S 1.08
P/FCF 11.78
P/OCF 8.78
P/B N/A
P/tB N/A
EV/EBITDA 8.39
EPS(TTM)0.74
EY7.54%
EPS(NY)0.92
Fwd EY9.38%
FCF(TTM)0.83
FCFY8.49%
OCF(TTM)1.12
OCFY11.39%
SpS9.08
BVpS-0.36
TBVpS-4.33
PEG (NY)0.43
PEG (5Y)1.25
Profitability
Industry RankSector Rank
ROA 0.1%
ROE N/A
ROCE 16.4%
ROIC 11.52%
ROICexc 11.84%
ROICexgc 23.31%
OM 13.31%
PM (TTM) 0.12%
GM 37.67%
FCFM 9.17%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexcg growth 3Y25.12%
ROICexcg growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 9.66
Debt/EBITDA 3.99
Cap/Depr 36.48%
Cap/Sales 3.14%
Interest Coverage 1.59
Cash Conversion 56.16%
Profit Quality 7750.49%
Current Ratio 1.43
Quick Ratio 0.88
Altman-Z 1.66
F-Score7
WACC11.09%
ROIC/WACC1.04
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.46%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%56.25%
EPS Next Y31.02%
EPS Next 2Y25.98%
EPS Next 3Y24.22%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%3.24%
Revenue Next Year8.32%
Revenue Next 2Y7.29%
Revenue Next 3Y7.7%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year11.33%
EBIT Next 3Y10.45%
EBIT Next 5Y3.87%
FCF growth 1Y129.81%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y76.74%
OCF growth 3Y6.86%
OCF growth 5Y180.48%